SCHEMBL285214

SCHEMBL285214

CCCCCCOC(=O)c1cccnc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 1.00
L3MBTL1 Q9Y468 1/20 0.89
MAPT P10636 4/20 0.81
ALDH1A1 P00352 4/20 0.81
KMT2A Q03164 2/20 0.81
MEN1 O00255 1/20 0.81
HPGD P15428 1/20 0.81
NFKB1 P19838 2/20 0.70
NFKB2 Q00653 2/20 0.70
RELA Q04206 2/20 0.70
NPC1 O15118 2/20 0.70
POLB P06746 1/20 0.70
SMN1; SMN2 Q16637 1/20 0.70
TSHR P16473 3/20 0.63
CYP1A2 P05177 1/20 0.63
CYP2C9 P11712 1/20 0.63
CYP2C19 P33261 1/20 0.63
RAB9A P51151 1/20 0.56
TDP1 Q9NUW8 1/20 0.55
TP53 P04637 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3402747 1.00 LMNA (1.00) LMNAL3MBTL1MAPTALDH1A1KMT2A
SCHEMBL6799776 1.00 LMNA (1.00) LMNAL3MBTL1MAPTALDH1A1KMT2A
SCHEMBL135491 1.00 LMNA (1.00) LMNAL3MBTL1MAPTALDH1A1KMT2A
SCHEMBL2939266 1.00 LMNA (1.00) LMNAL3MBTL1MAPTALDH1A1KMT2A
SCHEMBL10460555 1.00 LMNA (1.00) LMNAL3MBTL1MAPTALDH1A1KMT2A
SCHEMBL22092312 1.00 LMNA (1.00) LMNAL3MBTL1MAPTALDH1A1KMT2A
SCHEMBL9717064 1.00 LMNA (1.00) LMNAL3MBTL1MAPTALDH1A1KMT2A
SCHEMBL4275232 1.00 LMNA (1.00) LMNAL3MBTL1MAPTALDH1A1KMT2A
SCHEMBL589021 1.00 LMNA (1.00) LMNAL3MBTL1MAPTALDH1A1KMT2A
SCHEMBL9717062 1.00 LMNA (1.00) LMNAL3MBTL1MAPTALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 634 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12605345-B2 Transdermal drug delivery system BioPhysics Pharma, Inc. (US) 2026-04-21 US claimed
US-20250268841-A1 Trans-Epithelial Membrane Drug Delivery System Masiz, John J. (US) 2025-08-28 US claimed
WO-2025150056-A1 A HERBAL VAGINAL OIL IN WATER EMULSION GEL LUBRICANT AND METHOD OF PREPARATION THEREOF WAGHODE, Parag (IN) 2025-07-17 WO claimed
US-20250120907-A1 Transmucosal Drug Delivery System Masiz, John J. (US) 2025-04-17 US claimed
US-12246098-B2 Trans-epithelial membrane drug delivery system BioPhysics Pharma, Inc. (US) 2025-03-11 US claimed
CN-119015394-A Sulfur-containing compound preparation, and preparation method and application thereof 上海优斐斯生物科技有限公司 2024-11-26 CN claimed
US-20240216292-A1 Trans-Epithelial Membrane Drug Delivery System Masiz, John J. (US) 2024-07-04 US claimed
US-20240108588-A1 Transdermal Drug Delivery System Masiz, John J. (US) 2024-04-04 US claimed
US-11865217-B2 Transdermal drug delivery system BioPhysics Pharma, Inc. (US) 2024-01-09 US claimed
EP-3419588-B1 COMPOSITION FOR TOPICAL USE BASED ON A CARNOSINE-MAGNESIUM COMPLEX OUTPLAY INC (US) 2023-04-05 EP claimed
EP-1076549-B1 USE OF METALLOPROTINEASE INHIBITORS FOR INDUCING AND/OR STIMULATING GROWTH OF HAIR OR HAIRS AND/OR FOR SLOWING DOWN THEIR LOSS OREAL (FR) 2004-09-15 EP claimed
US-20020155962-A1 Nonaqueous hair styling composition and method of use ANDREW JERGENS COMPANY, THE 2002-10-24 US claimed
CN-1331967-A Powder cosmetics and/or make-up and care composition containing specific adhesive OREAL (FR) 2002-01-23 CN claimed
US-5658576-A Method for combatting cellulitis or reducing localized fatty excesses L'OREAL (FR) 1997-08-19 US claimed
US-5571503-A AQUEOUS EMULSION, PLANT EXTRACTS, PHOSPHOLIPIDS, FREE RADICAL SCAVENGERS CHANEL, INC. 1996-11-05 US claimed
EP-0655235-B1 Slimming composition OREAL (FR) 1996-08-07 EP claimed
EP-0371844-B1 USE OF ALPHA-TOCOPHEROL, BENZYL, XANTHINOL OR HEXYL NICOTINATE OR ALPHA TOCOPHEROL ACETATE IN A COSMETIC OR PHARMACEUTICAL SLIMMING COMPOSITION L'OREAL (FR) 1992-07-29 EP claimed
EP-0220825-B1 PHARMACEUTICAL COMPOSITION FOR TOPICAL APPLICATION DIOMED DEVELOPMENTS LIMITED (GB) 1989-09-06 EP claimed
US-4690818-A HAIR AND SKIN; CONTAIN COCODIMONIUM HYDROLYZED KERATIN AND MIXTURE OF MONO- AND DI-SACCHARIDES CHARLES OF THE RITZ GROUP LTD. (US) 1987-09-01 US claimed
EP-0220825-A2 Pharmaceutical composition for topical application DIOMED DEVELOPMENTS LIMITED (GB) 1987-05-06 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12605345-B2 Transdermal drug delivery system FABP2, VEGFA, CUTA LMNA 512/4885L3MBTL1 3949/4885MAPT 218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.